AMO Pharma: Encouraging Phase II Results for Congenital and Juvenile Myotonic Trial.
AMO Pharma has announced results from its ongoing phase II study investigating two doses of tideglusib (AMO-02) in adults with congenital...
top of page
Featured Posts
Recent Posts
Archive
Search By Tags
No tags yet.
Follow Us
bottom of page